Top

Published in:

26-07-2022 | Melanoma | ASO Author Reflections

ASO Author Reflections: Neoadjuvant Treatment for Melanoma—Where Are We Now?

Authors: Cimarron E. Sharon, MD, Giorgos C. Karakousis, MD

Published in: Annals of Surgical Oncology | Issue 13/2022

Excerpt

Management of patients with resectable stage III–IV cutaneous melanoma historically consisted of surgical resection upfront with consideration of adjuvant therapy. However, with the advent of systemic therapies (i.e., targeted therapy and immune checkpoint blockade) with significant antitumor activity, there has been an increasing interest in neoadjuvant approaches to patients with oligometastatic disease. Neoadjuvant therapy is advantageous as it can both downstage the tumor and theoretically “prime” the immune system to the circulating tumor antigens prior to resection. …

Sharon CE, Karakousis GC. Educational review: neoadjuvant approaches to melanoma. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12224-6.CrossRefPubMed

Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655–61. https://doi.org/10.1038/s41591-018-0198-0.CrossRefPubMed

Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948–60. https://doi.org/10.1016/S1470-2045(19)30151-2.CrossRefPubMed

Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178–88. https://doi.org/10.1038/s41591-022-01851-x.CrossRefPubMed

Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27(2):301–9. https://doi.org/10.1038/s41591-020-01188-3.CrossRefPubMed

Title: ASO Author Reflections: Neoadjuvant Treatment for Melanoma—Where Are We Now?
Authors: Cimarron E. Sharon, MD
Giorgos C. Karakousis, MD
Publication date: 26-07-2022
Publisher: Springer International Publishing
Keywords: Melanoma
Melanoma
Published in: Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-022-12308-3

At a glance: The STEP trials

Springer Medicine

ASO Author Reflections: Neoadjuvant Treatment for Melanoma—Where Are We Now?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 13/2022

ASO Visual Abstract: Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases

Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma?

ASO Author Reflections: How Immunotherapy Could Change the Management of Responsive Solid Tumors

Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo

Moving Forward with Omission of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy

ASO Visual Abstract: Natural History and Management of Small Bowel Obstruction in Patients After Cytoreductive Surgery and Intraperitoneal Chemotherapy